Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

July 2004 - Part 2

The Effect of Increases in HMO Penetration and Changes in Payer Mix on In-hospital Mortality and Treatment Patterns for Acute Myocardial Infarction

ByKevin G. M. Volpp, MD, PhD,Edward Buckley, MA

July 1st 2004

Impact of an Educational Intervention for Secondary Prevention of Myocardial Infarction on Medicaid Drug Use and Cost

ByIlene H. Zuckerman, PharmD,Sheila R. Weiss, PhD,Diane McNally, BPharm, MS,Barbara Layne, RN,C. Daniel Mullins, PhD,Junling Wang, MS

July 1st 2004

The Potential Role of Community-based Registries to Complement the Limited Applicability of Clinical Trial Results to the Community Setting: Heart Failure as an Example

ByJoseph A. Franciosa, MD

July 1st 2004

Hypertension Management: The Care Gap Between Clinical Guidelines and Clinical Practice

BySusan E. Andrade, ScD,Jerry H. Gurwitz, MD,Terry S. Field, DSc,Michael Kelleher, MD,Sumit R. Majumdar, MD, MPH,George Reed, PhD,Robert Black, MD

July 1st 2004

Can We Use Automated Data to Assess Quality of Hypertension Care?

ByAnn M. Borzecki, MD, MPH,Ashley T. Wong, MA,Elaine C. Hickey, RN, MS,Arlene S. Ash, PhD,Dan R. Berlowitz, MD, MPH

July 1st 2004

Improving Quality of Cardiovascular Care in the Real World: How Can We Remove the Barriers?

ByDebabrata Mukherjee, MD,Kim A. Eagle, MD

July 1st 2004

Aligning Financial Incentives With "Get With The Guidelines" to Improve Cardiovascular Care

ByJohn T. Berthiaume, MD,Patricia A. Tyler, RN, CCRN,Jacqueline Ng-Osorio, MPH,Kenneth A. LaBresh, MD

July 1st 2004

Trending on AJMC

Incretin Innovation, Metabolic Liver Disease, and Cardiovascular Risk Reduction Dominate ADA 2026

EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology

Paul Richardson, MD, Calls Mezigdomide “CAR T in a Pill” for Patients With R/R Multiple Myeloma

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD